公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2022 | Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial | Freemantle, Nick; Mollon, Patrick; Meyer, Tim; ANN-LII CHENG ; El-Khoueiry, Anthony B; Kelley, Robin K; Baron, Ari D; Benzaghou, Fawzi; Mangeshkar, Milan; Abou-Alfa, Ghassan K | European journal of cancer (Oxford, England : 1990) | 2 | 1 | |
2018 | Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection | HUNG-CHIH YANG ; Tsou H.-H; Pei S.-N; Chang C.-S; Chen J.-H; MING YAO ; Lin S.-J; Lin J; Yuan Q; Xia N; Liu T.-W; PEI-JER CHEN ; ANN-LII CHENG ; CHIUN HSU ; Taiwan Cooperative Oncology Group | Journal of Hepatology | 68 | 58 | |
1999 | Quiescent nasal T/NK cell lymphoma manifested as primary central nervous system lymphoma | KUN-HUEI YEH ; HUANG-CHUN LIEN ; Hsu S.-M.; ANN-LII CHENG | American Journal of Hematology | 31 | | |
2007 | Radiation-induced hepatitis B virus reactivation in liver mediated by the bystander effect from irradiated endothelial cells | Chia H.C.; PEI-JER CHEN ; PO-HUANG LEE ; ANN-LII CHENG ; Hsu H.-C.; CHIA-HSIEN CHENG | Clinical Cancer Research | 86 | 78 | |
2013 | Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size | ZHONG-ZHE LIN ; Shau W.-Y.; CHIUN HSU ; YU-YUN SHAO ; Yeh Y.-C.; Kuo R.N.-C.; CHIH-HUNG HSU ; CHIH-HSIN YANG ; ANN-LII CHENG ; Lai M.-S. | PLoS ONE | 26 | 24 | |
2014 | Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption | ZHONG-ZHE LIN ; Chou, Chia-Hung; ANN-LII CHENG ; Liu, Wei-Lin; CHIA-HSIEN CHENG | Int. J. Cancer | 17 | 15 | |
2012 | Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinoma | YEN-SHEN LU ; Chou C.-H.; KAI-YUAN TZEN ; Gao M.; ANN-LII CHENG ; Kulp S.K.; CHIA-HSIEN CHENG | International Journal of Radiation Oncology Biology Physics | 21 | 20 | |
2021 | Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression | Ryoo B.-Y.; ANN-LII CHENG ; Ren Z.; Kim T.-Y.; Pan H.; Rau K.-M.; Choi H.J.; Park J.-W.; Kim J.H.; Yen C.J.; Lim H.Y.; Zhou D.; Straub J.; Scheele J.; Berghoff K.; Qin S. | British Journal of Cancer | 20 | 17 | |
2013 | Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study | Ueno H.; Ioka T.; Ikeda M.; Ohkawa S.; Yanagimoto H.; Boku N.; Fukutomi A.; Sugimori K.; Baba H.; Yamao K.; Shimamura T.; Sho M.; Kitano M.; ANN-LII CHENG ; Mizumoto K.; Chen J.-S.; Furuse J.; Funakoshi A.; Hatori T.; Yamaguchi T.; Egawa S.; Sato A.; Ohashi Y.; Okusaka T.; Tanaka M.; 鄭安理 | Journal of Clinical Oncology | 508 | 467 | |
2016 | Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma | ANN-LII CHENG ; Thongprasert S.; Lim H.Y.; Sukeepaisarnjaroen W.; Yang T.-S.; Wu C.-C.; Chao Y.; Chan S.L.; Kudo M.; Ikeda M.; Kang Y.-K.; Pan H.; Numata K.; Han G.; Balsara B.; Zhang Y.; Rodriguez A.-M.; Zhang Y.; Wang Y.; Poon R.T.P. | Hepatology | 71 | 68 | |
2014 | Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel | ANN-LII CHENG ; Amarapurkar D.; Chao Y.; PEI-JER CHEN ; Geschwind J.-F.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; Park J.-W. | Liver International | 74 | 69 | |
2004 | Recent advances in non-surgical treatment for advanced hepatocellular carcinoma | CHIUN HSU ; CHIA-HSIEN CHENG ; ANN-LII CHENG | Journal of the Formosan Medical Association | 23 | 18 | |
2014 | Recent advances in the prevention of hepatocellular carcinoma recurrence | LI-CHUN LU ; ANN-LII CHENG ; Poon R.T.P. | Seminars in Liver Disease | 48 | 44 | |
2011 | Recent advances in the treatment of metastatic colorectal cancer in Taiwan | Lin Y.-L.; KUN-HUEI YEH ; ANN-LII CHENG | Journal of the Formosan Medical Association | 1 | 1 | |
2004 | Recent advances in therapy for gastric cancer | KUN-HUEI YEH ; ANN-LII CHENG | Journal of the Formosan Medical Association | 7 | 7 | |
2018 | Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma | Bouattour M.; Raymond E.; Qin S.; ANN-LII CHENG ; Stammberger U.; Locatelli G.; Faivre S. | Hepatology | 181 | 172 | |
2008 | Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia | Hong C.-C.; Lay J.-D.; Huang J.-S.; ANN-LII CHENG ; JIH-LUH TANG ; Lin M.-T.; Lai G.-M.; Chuang S.-E. | Cancer letters | 182 | 165 | |
2021 | Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages | DA-LIANG OU ; Chen C.-W.; CHIA-LANG HSU ; Chung C.-H.; Feng Z.-R.; Lee B.-S.; ANN-LII CHENG ; Yang M.-H.; CHIUN HSU | Journal for ImmunoTherapy of Cancer | 58 | 44 | |
2017 | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Bruix J.; Qin S.; Merle P.; Granito A.; Huang Y.-H.; Bodoky G.; Pracht M.; Yokosuka O.; Rosmorduc O.; Breder V.; Gerolami R.; Masi G.; Ross P.J.; Song T.; Bronowicki J.-P.; Ollivier-Hourmand I.; Kudo M.; ANN-LII CHENG ; Llovet J.M.; Finn R.S.; LeBerre M.-A.; Baumhauer A.; Meinhardt G.; Han G. | The Lancet | 2620 | 2396 | |
2016 | Relapse pattern and treatment outcome of curative radiotherapy for primary cutaneous CD30+ anaplastic large-cell lymphoma: A retrospective cohort study | Huang B.-S.; WAN-YU CHEN ; CHUN-WEI WANG ; ANN-LII CHENG ; Hong J.-H.; SUNG-HSIN KUO | Acta Dermato-Venereologica | 3 | 3 | |